Pfizer
Pfizer Temporarily Suspends Dosing in Advanced Duchenne Muscular Dystrophy (DMD) Trial After Patient Fatality
Pfizer, Duchenne Muscular Dystrophy (DMD), clinical trial, dosing halt, patient death, late-stage study, temporary suspension, safety concerns, investigation.
Pfizer Appoints Citi Analyst Andrew Baum as New Strategy Chief
Pfizer, Andrew Baum, Citi analyst, strategy chief, pharmaceutical industry, leadership change, strategic planning.
FDA Grants Full Approval to Pfizer’s Tivdak for Advanced Cervical Cancer Treatment
FDA, Pfizer, Tivdak, full approval, advanced cervical cancer, treatment, regulatory tracker
FDA Approval Milestones: X4 Pharmaceuticals, Pfizer, and Genmab Secure Nods for Rare Disease and Cervical Cancer Treatments
FDA, X4 Pharmaceuticals, Pfizer, Genmab, rare disease, cervical cancer, drug approval, treatment, healthcare, biotechnology.
Pfizer’s Revolutionary Hemophilia B Gene Therapy Gains FDA Approval and Introduces Unique Warranty Program
Pfizer, FDA, Hemophilia B, Gene Therapy, Approval, Warranty, Treatment, Genetic Disorder, Blood Clotting, Healthcare, Biotechnology
FDA Approves Pfizer’s Hemophilia B Gene Therapy with a $3.5 Million Price Tag
Pfizer, FDA, hemophilia B, gene therapy, approval, pricing, healthcare, biotechnology, rare diseases, genetic disorders, treatment cost.
GSK Files Lawsuit Against Pfizer and BioNTech for Alleged COVID-19 Vaccine Patent Violation
GSK, Pfizer, BioNTech, COVID-19, patent infringement, vaccine, lawsuit, intellectual property
AbbVie Emerges as Leading Immunology Company in Doctor Rankings, Surpassing Pfizer and Johnson & Johnson
AbbVie, Pfizer, Johnson & Johnson, doctor ranking, immunology companies, pharmaceutical industry, market performance, reputation, product portfolio.
Biopharma Layoff Tracker 2024: Sanofi, Vedanta, Fujifilm, and More Companies Reduce Workforce
Biopharma layoffs, Sanofi, Vedanta, Fujifilm, Acorda Therapeutics, Eiger BioPharmaceuticals, Invitae, Sientra, Strand Therapeutics, Cara Therapeutics, Pfizer
Pfizer Discontinues Phase III Trial for Sickle Cell Treatment Amid Challenges in Patient Recruitment
Pfizer, Sickle Cell Disease, Phase III Study, Inclacumab, Poor Accrual, Recruitment Challenges, THRIVE Program, ClinicalTrials.gov, Gene Therapies